Ackman's Pershing Square builds $954M Alcon stake
What's the deal? Pershing SquareDealroom has a profile for this one. Try Dealroom → acquired 14.7 million shares in AlconDealroom has a profile for this one. Try Dealroom → worth $954 million by the end of its latest reporting quarter, Yahoo Finance reported on November 19. The holding, disclosed in Bill Ackman's firm's third-quarter 13F filing, was measured as of September 30, 2026, and gives it a substantial position in the Swiss eye-care company.
Why now? The investment lands as Alcon faces weaker demand and sharper competition in implantable products. Its shares have been pressured by slower cataract procedures, softer US demand, and competition in intraocular lenses.
What's the endgame? Alcon's third-quarter net sales rose 5% year over year to $2.72 billion, while core diluted earnings per share climbed 15.2% to $0.91. Consumables and Vision Care grew, but implantables sales fell 2% as competition in the US intraocular-lens market intensified.
What could go wrong? Management narrowed its 2026 outlook. It expects constant-currency sales growth of about 6%, core operating margin expansion of 100 to 150 basis points, and core diluted earnings-per-share growth of 12% to 14% — numbers that leave less room for error if implantables keep sliding.
Alcon has continued to benefit from new surgical equipment, eye treatments, and broader portfolio growth, according to Yahoo Finance.
The signal: A closely watched activist-style investor taking a near-$1 billion position puts Alcon in focus at a moment when its growth is uneven. European equities remain central to current market reports, and Ackman's move adds a new investor angle to a company balancing resilient segments against implantables pressure.
Read more: ad-hoc-news.de
Image credit: "Alcon Freiburg-Hochdorf" by Gerd Fahrenhorst, licensed under CC BY 3.0